Author:
Zhang Yan,Chen Hui,Feng Nannan,Xin Xiangying,Xu Yue,Huo Pengchao,Wang Xuesong,Zhang Nan
Subject
Pharmaceutical Science,General Materials Science,Biomedical Engineering,Molecular Medicine,Medicine (miscellaneous),Bioengineering
Reference38 articles.
1. Dietary compounds and cutaneous malignant melanoma: recent advances from a biological perspective;Ombra;Nutr Metab (Lond),2019
2. Gefitinib inhibits malignant melanoma cells through the VEGF/AKT signaling pathway;Wan;Mol Med Rep,2018
3. Xiaojing Kang, MD, PhDa, Ying Zeng, MMa , Junqin Liang, MDa , Jing Li, MMa , Danyang Ren, MMa, Li Chai, PhDa . et al. Aberrations and clinical significance of BRAF in malignant melanoma: A series of 60 cases in Chinese Uyghur. Medicine (Baltimore) 97, e9509, doi:10.1097/MD.0000000000009509 (2018).
4. Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma;Skoko;BMC Cell Biol,2018
5. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents;Morin;Oncogene,2000
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献